While our main analysis focused on identifying patients at risk for sub-therapeutic dosing of 5-FU, we also performed an exploratory analysis of the association of fasting pretreatment plasma uracil concentration with carriage of deleterious DPYD gene variants strongly linked with DPD deficiency. This evidence concerns the gene DPYD and dihydropyrimidine dehydrogenase deficiency.